Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo

Cancer Lett. 2013 Oct 10;339(2):237-46. doi: 10.1016/j.canlet.2013.06.014. Epub 2013 Jun 18.

Abstract

Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133+ and Sca-1+ cells were unaltered following chemotherapy. CD133+ and Sca-1+ cells exhibited increased stem cell-related gene expression, were enriched in G0/G1-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease.

Keywords: CD133 cells; Ovarian cancer tumor initiating cells; Sca-1 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Animals
  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • Antigens, Ly / genetics
  • Antigens, Ly / metabolism
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Carboplatin / administration & dosage
  • Carboplatin / pharmacology*
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Glycoproteins / genetics
  • Glycoproteins / metabolism
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / metabolism*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology*
  • Paclitaxel / administration & dosage
  • Paclitaxel / pharmacology*
  • Peptides / genetics
  • Peptides / metabolism
  • Tumor Burden / drug effects

Substances

  • AC133 Antigen
  • Antigens, CD
  • Antigens, Ly
  • Antineoplastic Agents
  • Glycoproteins
  • Ly6a protein, mouse
  • Membrane Proteins
  • Peptides
  • Prom1 protein, mouse
  • Carboplatin
  • Paclitaxel